1229-29-4

• 常用中文名：盐酸多塞平
• 常用英文名：Doxepin hydrochloride
• CAS号：1229-29-4
• 分子式：C₁₉H₂₂ClNO
• 分子量：315.837
• 相关类别： 原料药 神经系统用药 抗抑郁、躁狂药
• 发布时间：2018-02-05 08:00:00
• 更新时间：2026-06-30 10:36:19
• Doxepin盐酸盐能抑制5-羟色胺和去甲肾上腺素的重吸收,有抗抑郁活性。

名称

• 中文名: 盐酸多虑平
• 英文名: Doxepin Hydrochloride
• 中文别名: 多虑平 盐酸盐 溶液; 盐酸多塞平(Z和E异构体混合物); 盐酸多塞平 标准品; 多虑平; 盐酸多虑平—禁止销售; 盐酸多噻平; 多塞平盐酸盐 标准品; 凯舒; 多塞平盐酸盐(1-4) 标准品; 盐酸多塞平(多虑平)标准品; 甲醇中盐酸多塞平(多虑平)溶液标准物质; 甲醇中盐酸多塞平; 盐酸多塞平(标准品); 3-(二苯并[B,E]氧杂卓-11(6H)-亚烷基)-N,N-二甲基丙-1-胺盐酸盐; N,N-二甲基-3-二苯并[b,e]-噁庚英-11(6H)亚基-丙胺盐酸盐; 多塞平/用于系统适用性试验/A1A; 多虑平 盐酸盐 (异构体混合物); N,N-二甲基-3-二苯并[B,E]-庚英-11(6H)亚基-丙胺盐酸盐; 盐酸多塞平,10 MM DMSO 溶液; 盐酸多塞平(Z和E异构体的混合物); 多虑平杂质; 盐酸多塞平溶液, 100PPM; 盐酸多塞平杂质; 盐酸多赛平; Doxin Hydrochloride 盐酸多塞平; 多虑平盐酸盐; DOXIN盐酸盐; 盐酸多塞平/盐酸多虑平; 盐酸多塞平DOXIN HYDROCHLORIDE; 盐酸多塞平原料; 2H6]-多虑平盐酸盐; 盐酸多塞平西酞普兰; 多塞平盐酸盐; 甲醇中多虑平盐酸盐标准溶液; 盐酸多巴胺对照品; 11-(3-二甲基氨基亚丙基)-6,11-二氢二苯并[b,e]氧杂卓盐酸盐; 多西塞平杂质
• 英文别名: Doxin hydrochloride CRS; 2H6]-Doxin hydrochloride salt; adapin; 1-Propanamine, 3-dibenzb,eoxin-11(6H)-ylidene-N,N-dimethyl-, hydrochloride; Doxin Hydrochloride 1.0 mg/ml in Methanol (as free base); 3-Dibenz(b,e)oxin-11(6H)-yliden-N,N-dimethyl-1-propanamin-hydrochlorid; 1-Propanamine, 3-dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-, hydrochloride (1:1); EINECS 214-966-8; Doxopin hydrochloride; Doxepin (Hydrochloride); doxepin HCl; Doxin Hydrochlorid; Sinequan; DOXIN HCL; (E)-3-(dibenzo[b,e]oxin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine hydrochloride; P 3693A; 11-(3-dimethylaminopropylidene)-6,11-dihydro-benz[b,e]oxin hcl; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo[b,e]oxine Hydrochloride; 11-dimethylaminopropylidene6h-dibenz(b,e)oxin; 3-(6,11-dihydrodibenz(b,e)oxin-11-ylidene)propyldimethylamine hcl; e)oxin-delta(sup11(6h),gamma)-propylamine,n,n-dimethyl-dibenz(hydrochlo; Doxin hydrochloride IMP; Doxin HCl (Mixture of Z and E Isomer); n,n-dimethyldibenz(b,e)oxin-delta(sup11(6h),gamma)-propylaminehydrochlori; p-4599; 11-(3-dimethylaminopropylidene)-6,11-dihydro-benz[b,e]oxin; Doxin.HCl, 1mg/ml in Methanol (as free base); 3-Dibenzo[b,e]oxepin-11(6H)-yliden-N,N-dimethylpropan-1-aminhydrochlorid; TIMTEC-BB SBB005916; 3-DIBENZ(B,C)OXIN 11(6H)YLIDENE-N,N-DIMETHYL-1-PROPANAMINE HYDROCHLORIDE; 3-dibez[b,e]oxin-11(6h)-ylidene-n,n-dimethyl-1-propanaminhydrochloride; Doxin HydrochlorideQ: What is Doxin Hydrochloride Q: What is the CAS Number of Doxin Hydrochloride Q: What is the storage condition of Doxin Hydrochloride Q: What e the applications of Doxin Hydrochloride; Doxin hydrochloride solution; 3-dibenz(b,e)oxin-11(6h)ylidene-n,n-dimethyl-1-propanaminhydrochloride; 1-Propanamine, 3-(dibenz[b,e]oxin-11(6H)-ylidene)-N,N-dimethyl-, hydrochloride (1:1); Doxin hydrochloride //BP; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine hydrochloride; Novoxapin; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepine hydrochloride; Doxin Hydrochloride >; 11[16H]-[3-(DIMETHYLAMINO)-PROPYLIDENE]DIBENZ[B,E]OXINE HYDROCHLORIDE; DOXINe HCL; 11-(3-DIMETHYLAMINOPROPYLIDENE)-6,11-DIHYDRODIBENZ[B,E]OXIN HYDROCHLORIDE; Doxine hydrochloride; DOXINHYDROCHLORIDE; 3-(Dibenzo[b,e]oxin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine hydrochloride; Doxin hydrochloride (cis+trans) in methanol; Adapin; N,N-Dimethyldibenz[b,e]oxepin-D11(6H),g-propylamine Hydrochloride; 1-propanamine, 3-dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-, hydrochloride; DOXIN HYDROCHLORIDE; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxine hydrochloride; Doxin hydrochloride, 10 mM in DMSO; Doxin Hydrochloride in methanol; N,N-Dimethyldibenz[b,e]oxepin-δ11(6H),γ-propylamine hydrochloride; Doxin hydrochloride (mixture of isomers); Doxin hydrochloride salt; Doxin HCl - Bio-X; Doxin hydrochloride,11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxine hydrochloride; Toruan; Curatin; 3-(Dibenzo[b,e]oxepin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine hydrochloride (1:1); cidoxinhydrochloride; 3-(Dibenzo[b,e]oxepin-11(6H)-ylidene)-N,N-dimethyl-1-propanamine hydrochloride (1:1); Quitaxon; MFCD00079135; Novoxapin [Ester]; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo[b,e]oxepine Hydrochloride; MF 10 HCl; 3-(dibenzo[b,e]oxepin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine hydrochloride

物化性质

• 沸点: 413.3ºC at 760mmHg
• 熔点: 187-189°C
• 分子式: C₁₉H₂₂ClNO
• 分子量: 315.837
• 闪点: 121.3ºC
• 精确质量: 315.138977
• PSA: 12.47000
• LogP: 4.76440
• 外观性状: 白色至灰白色粉末
• 蒸汽压: 4.87E-07mmHg at 25°C
• 储存条件: 库房通风低温干燥,与食品原料分开存放
• 稳定性: Store in Freezer at -20°C
• 水溶解性: 1 M HCl: 50 mg/mL

生物活性

• 描述: Doxepin盐酸盐能抑制5-羟色胺和去甲肾上腺素的重吸收,有抗抑郁活性。
• 相关类别:
  信号通路 >> 神经信号通路 >> 5-羟色胺转运蛋白
  研究领域 >> 神经疾病
• 参考文献:

  [1]. http://pdsp.med.unc.edu/pdsp.php

  [2]. Hajak, G., et al., Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry, 2001. 62(6): p. 453-63.

MSDS

Material Safety Data Sheet Section1. Identification of the substance Product Name: Doxepin HCl Synonyms: Section2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. H301:Toxic if swallowed H361:Suspected of damaging fertility or the unborn child P281:Use personal protective equipment as required P301+P310:IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician P308+P313:IF exposed or concerned: Get medical advice/attention P321:Specific treatment (see on this label) P405:Store locked up Section3. Composition/information on ingredients. Ingredient name:Doxepin HCl CAS number:1229-29-4 Section4. First aid measures Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution:Wear approved mask/respirator Hand precaution:Wear suitable gloves/gauntlets Skin protection:Wear suitable protective clothing Eye protection:Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section7. Handling and storage Handling:This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Storage:Store in closed vessels. Section8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section9. Physical and chemical properties Appearance:Not specified No data Boiling point: Melting point:No data Flash point:No data Density:No data Molecular formula: C19H21NO.ClH Molecular weight: 315.8 Section10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride. Section11. Toxicological information No data. Section12. Ecological information No data. Section13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section14. Transportation information UN Number:UN2811Class: 6.1Packing group: III Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (Doxepin HCl) Section15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : HQ4375000 CHEMICAL NAME : Dibenz(b,e)oxepin-delta(sup 11(6H),gamma)-propylamine, N,N-dimethyl-, hydrochloride CAS REGISTRY NUMBER : 1229-29-4 LAST UPDATED : 199706 DATA ITEMS CITED : 29 MOLECULAR FORMULA : C19-H21-N-O.Cl-H MOLECULAR WEIGHT : 315.87 WISWESSER LINE NOTATION : T C676 IO&T&J B3N1&1 &GH HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 357 ug/kg TOXIC EFFECTS : Behavioral - muscle weakness Behavioral - coma Vascular - BP lowering not characterized in autonomic section REFERENCE : JATOD3 Journal of Analytical Toxicology. (Preston Pub. Inc., POB 48312, Niles, IL 60648) V.1- 1977- Volume(issue)/page/year: 7,161,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 112 mg/kg/4W-I TOXIC EFFECTS : Behavioral - hallucinations, distorted perceptions REFERENCE : JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 44,106,1983 TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human DOSE/DURATION : 90 mg/kg TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Behavioral - coma Blood - hemorrhage REFERENCE : JATOD3 Journal of Analytical Toxicology. (Preston Pub. Inc., POB 48312, Niles, IL 60648) V.1- 1977- Volume(issue)/page/year: 2,18,1978 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human DOSE/DURATION : 9300 ug/kg TOXIC EFFECTS : Behavioral - hallucinations, distorted perceptions Behavioral - muscle contraction or spasticity Cardiac - change in rate REFERENCE : JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year: 237,2632,1977 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 141 mg/kg/12W-I TOXIC EFFECTS : Sense Organs and Special Senses (Ear) - tinnitus REFERENCE : SMJOAV Southern Medical Journal. (Southern Medical Assoc., POB 2446, Birmingham, AL 35205) V.1- 1908- Volume(issue)/page/year: 76,1204,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 357 ug/kg TOXIC EFFECTS : Liver - hepatitis (hepatocellular necrosis), zonal Liver - jaundice (or hyperbilirubinemia) hepatocellular REFERENCE : ANZJB8 Australian and New Zealand Journal of Medicine. (Modern Medicine of Australia Pty., Ltd., 100 Pacific Highway, North Sydney, 2060, Australia) V.1- 1971- Volume(issue)/page/year: 23,523,1993 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 147 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,72,1972 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 84 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,889,1972 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 155 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - cyanosis REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,889,1972 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 13 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,72,1972 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 180 mg/kg TOXIC EFFECTS : Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,889,1972 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 79 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,72,1972 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 160 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,72,1972 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 15 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,72,1972 TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 300 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - convulsions or effect on seizure threshold Gastrointestinal - nausea or vomiting REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,889,1972 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >27 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - convulsions or effect on seizure threshold Gastrointestinal - nausea or vomiting REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,889,1972 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 40 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - convulsions or effect on seizure threshold Gastrointestinal - nausea or vomiting REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,889,1972 TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Primate - monkey DOSE/DURATION : 20400 ug/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Vascular - BP lowering not characterized in autonomic section REFERENCE : IJEBA6 Indian Journal of Experimental Biology. (Publications & Information Directorate, CSIR, Hillside Rd., New Delhi 110 012, India) V.1- 1963- Volume(issue)/page/year: 22,539,1984 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 11 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : 27ZQAG "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972 Volume(issue)/page/year: -,72,1972 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 14560 mg/kg/26W-C TOXIC EFFECTS : Cardiac - changes in heart weight Liver - changes in liver weight Kidney, Ureter, Bladder - changes in bladder weight REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,929,1972 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 3300 mg/kg/33D-C TOXIC EFFECTS : Gastrointestinal - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 6,889,1972 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1620 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,913,1971 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1620 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,913,1971 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 60 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,913,1971 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 540 mg/kg SEX/DURATION : female 9-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,913,1971 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 210 mg/kg SEX/DURATION : female 8-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - live birth index (measured after birth) REFERENCE : DPTHDL Developmental Pharmacology and Therapeutics. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 8,17,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 900 mg/kg SEX/DURATION : female 8-16 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetal death REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,905,1971 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 45 mg/kg SEX/DURATION : female 8-16 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,905,1971 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3181 No. of Facilities: 140 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 2633 (estimated) No. of Female Employees: 1442 (estimated)

安全

• 符号: GHS02, GHS06, GHS08
• 信号词: Danger
• 危害声明: H225-H301 + H311 + H331-H370
• 警示性声明: P210-P260-P280-P301 + P310-P311
• 个人防护装备: Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
• 危害码 (欧洲): T,F
• 风险声明 (欧洲): R25
• 安全声明 (欧洲): 36/37/39-45
• 危险品运输编码: UN 2811 6.1/PG 3
• WGK德国: 3
• RTECS号: HQ4375000
• 包装等级: III
• 危险类别: 6.1(b)
• 海关编码: 2932999099

合成路线

724-98-1 ~% 1229-29-4

文献：Synthetic Communications, , vol. 19, # 19 p. 3349 - 3352

139-02-6 ~% 1229-29-4

文献：Synthetic Communications, , vol. 19, # 19 p. 3349 - 3352

7115-91-5 ~% 1229-29-4

文献：Synthetic Communications, , vol. 19, # 19 p. 3349 - 3352

19070-16-7 4504-87-4 ~% 1229-29-4

文献：Synthetic Communications, , vol. 19, # 19 p. 3349 - 3352

4504-87-4 109-54-6 ~% 1229-29-4

文献：Synthetic Communications, , vol. 11, # 3 p. 241 - 246

上下游产品

上游产品  6
724-98-1 139-02-6 7115-91-5 19070-16-7
4504-87-4 109-54-6
下游产品  6
4504-87-4 250331-52-3 250331-53-4 250331-54-5
1668-19-5 1225-56-5

海关

海关编码	2932999099
中文概述	2932999099. 其他仅含氧杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途
Summary	2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%